In the November/December 2015 issue of PharmaVOICE, Rhett Johnson explains that to achieve better value, the health care industry must define what value looks like and measure how effectively it is being produced. To read the article, click here.
Part 2: Low-priced oncology disruptors: The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Healthcare coverage is heterogeneous across emerging markets, with public funding limited by budgetary constraints. This typically sees higher-priced drugs,...